Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Imlunestrant - Eli Lilly and Company/Loxo Oncology

Next Previous
Drug Profile

Imlunestrant - Eli Lilly and Company/Loxo Oncology

Alternative Names: LY-3484356

Latest Information Update: 25 Jul 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eli Lilly and Company
  • Class Antineoplastics; Azetidines; Benzopyrans; Fluorinated hydrocarbons; Heterocyclic compounds with 4 or more rings; Phenyl ethers; Quinolines; Small molecules
  • Mechanism of Action Selective estrogen receptor degraders
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration HER2 negative breast cancer
  • Phase I Endometrial cancer

Most Recent Events

  • 25 Jul 2025 Eli Lilly and Company expects regulatory action for approval of Imlunestrant for Her2-negative breast cancer in US and Japan in 2025
  • 02 Jun 2025 Preregistration for HER2-negative-breast-cancer (Metastatic disease) in European Union, European Union, Japan, USA (PO)
  • 25 Apr 2025 Adverse events, pharmacokinetics and efficacy data from a phase I trial in Breast cancer presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top